# Elypta

Source: https://onco.cc/companies/elypta/  
OnCo record `elypta` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Elypta, of Stockholm, measures glycosaminoglycans, sugar molecules in blood and urine, and scores them with machine learning to detect kidney cancer returning after surgery; a second programme tests whether the same signature can flag any cancer early in symptom-free adults. Only interim data support the screening use.

## Summary

Elypta, based in Solna, Stockholm, has developed a metabolism-based liquid biopsy that profiles the glycosaminoglycan (GAG) composition of blood and urine (the GAGome), using its MIRAM kit and machine-learning scores to detect cancer-specific signatures; the company is ISO 13485 certified. Its first application is recurrence monitoring after kidney cancer surgery: the AURORAX programme, described as the largest such study, reached study end in May 2025. A second programme applies GAGome scores to multi-cancer early detection in asymptomatic adults, with interim data suggesting urine GAGs may predict risk of any cancer. Funding includes a EUR 2.35 million Horizon 2020 grant (2019), a EUR 6.1 million late seed led by Industrifonden (2020), a $21 million Series A led by Bonnier Ventures (2022) and a $1 million Roddenberry prize (2023).

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Stockholm
- Type: diagnostics
- Website: https://www.elypta.com/

## Notes

- Founding year not stated (earliest news item is July 2017). The Horizon 2020 grant and Roddenberry prize are described on the news listing page but not recorded as rounds because their individual pages were not fetched.

## Sources

- Official website: https://www.elypta.com/
- Series A press release (Jun 2022): https://www.elypta.com/news/elypta-raises-21-million-series-a-to-develop-metabolism-based-multi-cancer-early-detection-test
- News page: https://www.elypta.com/news

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/elypta.json